IV ARTESUNATE PLUS ACT Vs IV QUININE PLUS ACT AND EVALUATION OF PHARMACOKINETICS OF ARTEMETHER-LUMEFANTRINE AND DIHYDROARTEMISININ-PIPERAQUINE

Conditions

Malaria

Byakika-Kibwika P, Ssenyonga R, Lamorde M, Blessborn D, Tarning J.

2019-12-034 citations

Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial.

Byakika-Kibwika P, Nyakato P, Lamorde M, Kiragga AN.

2018-10-3011 citations

10.1186/s12936-018-2552-6

Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial.

Byakika-Kibwika P, Achan J, Lamorde M, Karera-Gonahasa C, Kiragga AN, Mayanja-Kizza H, Kiwanuka N, Nsobya S, Talisuna AO, Merry C.

2017-12-2812 citations

10.1186/s12879-017-2924-5

Interventions

Intravenous quinine plus ACT

IV artesunate plus ACT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age 6 months and above 2) With a positive blood smear for P. falciparum asexual parasitaemia with no other cause of the symptoms 3) Who meet the WHO clinical or laboratory criteria for severe malaria requiring parenteral therapy 3) Whose parents/caretakers provide written informed consent and are willing to participate in 42 day follow up

Exclusion criteria

Exclusion criteria: 1) Administration of any additional antimalarial drugs that are not study drugs within 72 hours before study enrolment and during the course of the study. 2) Emergence of any non-malarial febrile illness which may interfere with the classification of malaria treatment outcome 3) Movement away from the study area interfering with follow-up assessment 4) Patients with contraindications to taking the study drugs 5) Withdrawal of consent

Design outcomes

Primary

Measure	Time frame
Treatment failure unadjusted by genotyping	—

Secondary

Measure	Time frame
Treatment failure adjusted by genotyping;Time to event outcomes including: fever and parasite clearance times, coma recovery time, time to begin oral intake and time to sit up unsupported;Haemoglobin recovery on day 28;Adverse events	—

Countries

Uganda

Contacts

Public ContactMOHAMMED LAMORDE

CO-INVESTIGATOR

mlamorde@idi.co.ug+256 772 185590

Outcome results

None listed